Targeting Inflammation-Driving Enzyme May Lower Heart Disease Risk in Obese Individuals

Recent research led by Dr. Mathias Martin from the University of Cologne has uncovered promising insights into reducing cardiovascular risks associated with obesity. The study focused on the enzyme myeloperoxidase (MPO), which plays a significant role in inflammatory processes within the body. Elevated levels of MPO have been linked with poorer vascular function in obese patients and animal models. In particular, MPO accumulates in perivascular adipose tissue (PVAT)—a fatty tissue surrounding the aorta—that is crucial in maintaining blood vessel health.

The researchers found that in individuals with obesity, MPO activity promotes inflammation in PVAT and hampers the protective mechanisms that keep blood vessels elastic and functional. To explore this further, the team studied mice lacking MPO. These animals showed improved vascular function, reduced inflammation in PVAT, and a shift of fatty tissue into a more energy-consuming, active state. Furthermore, these mice exhibited higher levels of adiponectin, a hormone known for its beneficial effects on blood vessels.

The findings suggest that inhibiting MPO could be a promising therapeutic strategy to mitigate cardiovascular risk in obese individuals. However, further clinical studies are necessary to confirm the safety and effectiveness of such interventions before they can be adopted in medical practice.

This research was published under the title "Myeloperoxidase impacts vascular function by altering perivascular adipocytes' secretome and phenotype in obesity" in Cell Reports Medicine. It provides new avenues for understanding how inflammation contributes to vascular deterioration in obesity and how targeted enzyme inhibition might help in developing advanced treatments.

[Source: Medical Xpress]